These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 18052761)

  • 1. Role of tolcapone in the treatment of Parkinson's disease.
    Leegwater-Kim J; Waters C
    Expert Rev Neurother; 2007 Dec; 7(12):1649-57. PubMed ID: 18052761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.
    Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of tolcapone in fluctuating Parkinson's disease.
    Stocchi F; De Pandis MF
    Clin Interv Aging; 2006; 1(4):317-25. PubMed ID: 18046910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolcapone in the management of Parkinson's disease.
    Leegwater-Kim J; Waters C
    Expert Opin Pharmacother; 2006 Nov; 7(16):2263-70. PubMed ID: 17059382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolcapone: a review of its use in the management of Parkinson's disease.
    Keating GM; Lyseng-Williamson KA
    CNS Drugs; 2005; 19(2):165-84. PubMed ID: 15697329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM; Rinne UK
    J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
    Guay DR
    Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.
    Borges N
    Expert Opin Drug Saf; 2005 Jan; 4(1):69-73. PubMed ID: 15709899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.
    Factor SA; Molho ES; Feustel PJ; Brown DL; Evans SM
    Clin Neuropharmacol; 2001; 24(5):295-9. PubMed ID: 11586115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
    Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
    Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Bad guys' among the antiparkinsonian drugs.
    Pirtosek Z
    Psychiatr Danub; 2009 Mar; 21(1):114-8. PubMed ID: 19270634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Benabou R; Waters C
    Expert Opin Drug Saf; 2003 May; 2(3):263-7. PubMed ID: 12904105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.
    Borges N
    Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of COMT inhibition on levodopa pharmacology and therapy.
    Goetz CG
    Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
    Kurth MC; Adler CH; Hilaire MS; Singer C; Waters C; LeWitt P; Chernik DA; Dorflinger EE; Yoo K
    Neurology; 1997 Jan; 48(1):81-7. PubMed ID: 9008498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.